F. Graf Finckenstein

9.5k total citations
10 papers, 58 citations indexed

About

F. Graf Finckenstein is a scholar working on Oncology, Cancer Research and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, F. Graf Finckenstein has authored 10 papers receiving a total of 58 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cancer Research and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in F. Graf Finckenstein's work include Cancer Immunotherapy and Biomarkers (6 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and CAR-T cell therapy research (3 papers). F. Graf Finckenstein is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and CAR-T cell therapy research (3 papers). F. Graf Finckenstein collaborates with scholars based in United States, Spain and Germany. F. Graf Finckenstein's co-authors include Ian D. Davis, Renunda Hicks, Lara Lipton, Benjamin Solomon, Jayesh Desai, Pamela L. Clemens, Martin Steins, Leora Horn, Fabrice Barlési and Angela Brodie and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

F. Graf Finckenstein

10 papers receiving 57 citations

Peers

Countries citing papers authored by F. Graf Finckenstein

Since Specialization

Citations

This map shows the geographic impact of F. Graf Finckenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Graf Finckenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Graf Finckenstein more than expected).

Fields of papers citing papers by F. Graf Finckenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Graf Finckenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Graf Finckenstein. The network helps show where F. Graf Finckenstein may publish in the future.

Co-authorship network of co-authors of F. Graf Finckenstein

This figure shows the co-authorship network connecting the top 25 collaborators of F. Graf Finckenstein. A scholar is included among the top collaborators of F. Graf Finckenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Graf Finckenstein. F. Graf Finckenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	MA15.08 Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naïve Metastatic NSCLC 2023 ·Journal of Thoracic Oncology ·(unknown), Kai He, (unknown), Edward B. Garon, Jorge J. Nieva, Adrian G. Sacher, (unknown), F. Graf Finckenstein, Rana Fiaz, (unknown), (unknown), (unknown), Ben Creelan	3
2	844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody 2022 ·Annals of Oncology ·James Larkin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), F. Graf Finckenstein, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
3	EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC 2022 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), F. Graf Finckenstein, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
4	187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours 2021 ·Journal of Thoracic Oncology ·Scott Gettinger, Harriet M. Kluger, Adam J. Schoenfeld, Allison Betof Warner, Kai He, Ammar Sukari, Sajeve Thomas, (unknown), (unknown), Simon Haefliger, Zelanna Goldberg, (unknown), Rana Fiaz, (unknown), Madan Jagasia, F. Graf Finckenstein, Maria Fardis, Antonio Jimeno	1
5	417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs) 2015 ·Annals of Oncology ·Leora Horn, Julie R. Brahmer, Martin Reck, Hossein Borghaei, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Marco Angelo Burgio, Jérôme Fayette, Scott Gettinger, Christopher Harbison, A. Li, F. Graf Finckenstein, Luis Paz‐Ares	7
6	3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs) 2015 ·European Journal of Cancer ·Leora Horn, (unknown), Martin Reck, Hossein Borghaei, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Marco Angelo Burgio, (unknown), Scott Gettinger, Christopher Harbison, (unknown), F. Graf Finckenstein, Luis Paz‐Ares	5
7	Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. 2011 ·Journal of Clinical Oncology ·(unknown), Arindam Dhar, Xiaoming Hou, (unknown), Dimitry S.A. Nuyten, (unknown), Angela Brodie, J. N. Ingle, Joan M. Carboni, (unknown), Antonio C. Wolff, F. Graf Finckenstein	10
8	412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors 2010 ·European Journal of Cancer Supplements ·Quincy Chu, (unknown), Peter Ellis, Linda Mileshkin, Richard H. De Boer, (unknown), Theodore C. Pellas, (unknown), F. Graf Finckenstein, Arindam Dhar	2
9	Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. 2010 ·Journal of Clinical Oncology ·Jayesh Desai, Benjamin Solomon, Ian D. Davis, Lara Lipton, Renunda Hicks, (unknown), (unknown), Pamela L. Clemens, (unknown), F. Graf Finckenstein	25
10	Effect of IGF-1R inhibitor BMS-754807 on tumor glucose metabolism and proliferation in Sal-IGF xenografts by FDG and FLT- PET imaging 2009 ·Journal of Clinical Oncology ·Patrick L Chow, (unknown), David Kan, Ricardo M. Attar, F. Graf Finckenstein, Joan M. Carboni, Susan Galbraith, (unknown), Marco M. Gottardis, Bala Krishnan	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact